Related Experiment Video
Updated: Dec 13, 2025
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.9K
Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants
Steven J Smith1, Gary T Pauly2, Katharine Hewlett1
1HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Chemical Biology & Drug Design
|August 4, 2020
Summary
Novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) were developed to combat HIV-1 resistance. The best analog showed improved potency against resistant mutants, guiding future NNRTI design strategies.
Area of Science:
- Medicinal Chemistry
- Virology
- Drug Discovery
Background:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are crucial in HIV-1 antiretroviral therapy, often used in combination regimens.
- The development of two-drug maintenance therapies has spurred interest in novel NNRTIs effective against resistant strains.
- Existing NNRTIs face challenges with viral resistance, necessitating the design of new compounds.
Purpose of the Study:
- To design and synthesize novel rilpivirine (RPV) analogs targeting NNRTI-resistant HIV-1 mutants.
- To investigate structure-activity relationships for modifications around the RPV core.
- To provide insights for the development of next-generation NNRTIs.
Main Methods:
- Synthesis of novel RPV analogs based on structural modifications.
- Antiviral testing of synthesized compounds against NNRTI-resistant HIV-1 mutants.
- Evaluation of compound potency compared to existing NNRTIs like doravirine, efavirenz, and RPV.
Main Results:
- A novel RPV analog, compound 12, demonstrated enhanced inhibition of tested NNRTI-resistant mutants compared to doravirine and efavirenz.
- Compound 12's potency was superior to doravirine and efavirenz but inferior to RPV against the resistant strains.
- The study identified limitations in modifying the RPV core and explored the impact of alternative core structures.
Conclusions:
- Novel RPV analogs can be designed to overcome NNRTI resistance in HIV-1.
- Understanding structural limitations is key for optimizing NNRTI efficacy against resistant mutants.
- The findings offer valuable guidance for the rational design of improved NNRTIs for HIV-1 treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:29Subviral Agents
362
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
362
01:29Viruses with RNA Genomes
540
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
540